Delaying the Progression of Type 1 Diabetes: Managed Care Considerations on the Role of
New and Emerging Therapies

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Sanofi US

Description:
Type 1 diabetes (once called insulin-dependent or juvenile) is a chronic condition in which the pancreas produces very little or no insulin, a hormone produced by the pancreas to regulate the amount of glucose in the blood. Typically appearing in adolescence, type 1 diabetes is much less common than type 2, making up 5-10% of total diabetes cases in the United States. According to the American Diabetes Association, 1.6 million Americans have type 1 diabetes, including 187,000 children and adolescents. T1D impacts approximately 1 in 300 school-aged children in the US and the cognitive deficits have the potential to affect the growth and neuropsychological development of young children if not managed properly. Fortunately for patients with earlier stages of T1D, the treatment paradigm has expanded in the last year, giving managed care professionals and clinicians more options for managing these patients. This activity will feature strategies to overcome challenges in the optimal management of T1D and highlight the role of managed care professionals in making informed decisions on therapies that will improve quality of life, delay the disease progression, and minimize costs and the burden of disease.

Upon completion of this activity, participants will be able to:

• Assess the clinical and economic burden of type 1 diabetes (T1D), including factors that contribute to poor prognosis and increased costs
• Examine the importance of screening and staging of high-risk individuals for the development of T1D
• Explore the consequences of delayed diagnosis of T1D and how delays can increase the risk of diabetic ketoacidosis
• Analyze recent clinical trial data and the mechanisms of action of emerging treatments for delaying the progression to clinically manifested T1D, including those that demonstrated superior beta cell preservation assessed by significantly slowing the decrease in mean C-peptide levels
• Discuss the managed care considerations of emerging monoclonal antibodies for delaying the progression to clinically manifested T1D

Faculty:
Marian Rewers, MD, PhD
Professor of Pediatrics & Medicine
Richard S. Abrams Endowed Chair
Executive Director, Barbara Davis Center for Diabetes
University of Colorado School of Medicine
marian.rewers@cuanschutz.edu

Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Rewers has served as a consultant for Sanofi. He has received grant/research support from Sanofi. All relevant financial relationships have been mitigated.

Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)^TM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.

This activity is supported by an educational grant from
Sanofi US

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.